表紙
市場調査レポート

筋萎縮性側索硬化症:世界の治験レビュー

Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H2, 2016

発行 GlobalData 商品コード 239400
出版日 ページ情報 英文 182 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
筋萎縮性側索硬化症:世界の治験レビュー Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H2, 2016
出版日: 2016年08月17日 ページ情報: 英文 182 Pages
概要

当レポートでは、筋萎縮性側索硬化症に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、主な先進国・新興国における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤などの情報を盛り込んで、概略以下の構成でお届けします。

目次

イントロダクション

  • 筋萎縮性側索硬化症
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の上位5ヶ国
    • 欧州の上位5ヶ国
    • 北米の主要国
    • 中東・アフリカの主要国
    • 中南米の主要国

G7諸国での治験件数:中枢神経系疾患の治験全体における筋萎縮性側索硬化症の割合

G7諸国での治験件数:フェーズ(相)別

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:中枢神経系疾患の治験全体における筋萎縮性側索硬化症の割合

E7諸国での治験件数:フェーズ(相)別

E7諸国での治験件数:進捗状況別

フェーズ(相)別の治験件数

  • 進行中の治験:フェーズ別

進捗状況別の治験件数

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

  • 筋萎縮性側索硬化症治療薬の治験に参加している上位企業

有望な薬剤

治験のプロファイル

  • 代表的企業の治験の概要
    • Biogen Idec Inc.
    • Cytokinetics, Incorporated
    • Trophos SA
    • Teva Pharmaceutical Industries Limited
    • Phoenix Neurological Associates, Ltd.
    • Novartis AG
    • NeuroNova AB
    • Neuralstem, Inc.
    • 三菱ケミカルホールディングス
    • Avanir Pharmaceuticals, Inc.
  • 代表的な研究機関・病院の治験の概要
    • Massachusetts General Hospital
    • Drexel University College of Medicine
    • National Institute of Neurological Disorders and Stroke
    • University of Miami
    • Mayo Clinic
    • Charite - Universitatsmedizin Berlin
    • National Institute of Environmental Health Sciences
    • U.S. Department of Veterans Affairs
    • Johns Hopkins University
    • Assistance Publique - Hopitaux de Paris

5つの代表的な治験のプロファイル

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC3648CTIDB

GlobalData's clinical trial report, "Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H2, 2016" provides an overview of Amyotrophic Lateral Sclerosis clinical trials scenario. This report provides top line data relating to the clinical trials on Amyotrophic Lateral Sclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • Clinical Trials by Region 6
  • Clinical Trials and Average Enrollment by Country 7
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
  • Top Five Countries Contributing to Clinical Trials in Europe 10
  • Top Countries Contributing to Clinical Trials in North America 11
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 12
  • Top Countries Contributing to Clinical Trials in Central and South America 13
  • Clinical Trials by G7 Countries: Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials 14
  • Clinical Trials by Phase in G7 Countries 15
  • Clinical Trials in G7 Countries by Trial Status 16
  • Clinical Trials by E7 Countries: Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials 17
  • Clinical Trials by Phase in E7 Countries 18
  • Clinical Trials in E7 Countries by Trial Status 19
  • Clinical Trials by Phase 20
  • In Progress Trials by Phase 21
  • Clinical Trials by Trial Status 22
  • Clinical Trials by End Point Status 23
  • Subjects Recruited Over a Period of Time 24
  • Clinical Trials by Sponsor Type 25
  • Prominent Sponsors 26
  • Top Companies Participating in Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials 27
  • Prominent Drugs 29
  • Latest Clinical Trials News on Amyotrophic Lateral Sclerosis 30
  • Jul 20, 2016: The ALS Association and ALS Finding a Cure Announce Joint Funding Support for Amylyx Clinical Trial of AMX0035 for the Treatment of ALS 30
  • Jul 18, 2016: BrainStorm Announces Positive Top Line Results from the U.S. Phase 2 Study of NurOwn in Patients with Amyotrophic Lateral Sclerosis (ALS) 30
  • Jul 11, 2016: AB Science Announces The Publication In The Journal Of Neuroinflammation Of Preclinical Data Showing Neuroprotective Effect Of Masitinib In Amyotrophic Lateral Sclerosis 32
  • Clinical Trial Profile Snapshots 33

Appendix 179

  • Abbreviations 179
  • Definitions 179
  • Research Methodology 180
  • Secondary Research 180
  • About GlobalData 181
  • Contact Us 181
  • Disclaimer 181
  • Source 182

List of Tables

List of Tables

  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Region, 2016* 6
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 12
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 13
  • Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2016* 14
  • Amyotrophic Lateral Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
  • Amyotrophic Lateral Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
  • Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2016* 17
  • Amyotrophic Lateral Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
  • Amyotrophic Lateral Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Phase, 2016* 20
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
  • Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

List of Figures

List of Figures

  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 12
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 13
  • Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2016* 14
  • Amyotrophic Lateral Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
  • Amyotrophic Lateral Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
  • Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2016* 17
  • Amyotrophic Lateral Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
  • Amyotrophic Lateral Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
  • Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
  • GlobalData Methodology 180
Back to Top